This is also a part of the article that i wanted to share.
The safer bet in hospitalized COVID-19 is TOMDF and their Tollovir. They have been seeking an EUA in either Greece or Israel for the past couple of months after their clinical data showed a 100% reduction in mortality. At a $16 million market cap, an EUA could easily send the stock into the stratosphere to match VERU’s $800 million market cap. In their Phase 2 clinical trial Tollovir beat Gilead’s remdesivir and took dying off the table, but their study wasn’t powered high enough. Nor did they have the PR headlines that the trial was stopped early for efficacy even though it technically was. Investors may still take issue with the power of the study and unbelievably good results, but Tollovir targets the same biological target, the 3CL protease, as Pfizer’s (NYSE: PFE) drug Paxlovid, which displayed incredible efficacy in the outpatient setting, reducing hospitalizations and death by 89%. PFE’s 3CL inhibition is a proven Mechanism of Action (MOA) which makes TOMDF’s results very believable. The primary differences between the drugs are the safety due to Tollovir’s all natural composition versus Paxlovid’s small molecule chemical design. Tollovir also has an anti-inflammatory aspect in addition to its antiviral properties.
AI
Market Data 
Markets 
